UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 87

Sortiert nach

Coagulation assay discrepancies in Japanese patients with non-severe hemophilia A

International journal of hematology, 2022-02, Vol.115 (2), p.173-187

2022

Volltextzugriff (PDF)

Prolonged α-thrombin-related activation and delayed active protein C-associated degradation confer mild phenotype in a patient with severe hemophilia A with F8 p.H118R

International journal of hematology, 2022-10, Vol.116 (4), p.489-499

2022

Volltextzugriff (PDF)

In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab

Thrombosis research, 2023-02, Vol.222, p.131-139

2023

Volltextzugriff (PDF)

ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database

International journal of hematology, 2023-01, Vol.117 (1), p.44-55

2023

Volltextzugriff (PDF)

Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report

International journal of hematology, 2022-10, Vol.116 (4), p.622-629

2022

Volltextzugriff (PDF)

Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023-02, Vol.29 (2), p.171-178

2023

Volltextzugriff (PDF)

Effects of low and high factor X concentrations on thrombin generation in vitro

Thrombosis update, 2022-08, Vol.8, p.100111, Article 100111

2022

Volltextzugriff (PDF)

Serious hazards of transfusion: evaluating the dangers of a wrong patient autologous salvaged blood in cardiac surgery

Journal of cardiothoracic surgery, 2022-08, Vol.17 (1), p.1-182, Article 182

2022

Volltextzugriff (PDF)

Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial

BMJ open, 2022-02, Vol.12 (2), p.e056922-e056922

2022

Volltextzugriff (PDF)

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

Molecular therapy. Methods & clinical development, 2022-12, Vol.27, p.404-414

2022

Volltextzugriff (PDF)

Adherence to anti-retroviral therapy, decisional conflicts, and health-related quality of life among treatment-naïve individuals living with HIV: a DEARS-J observational study

Journal of pharmaceutical health care and sciences, 2023-03, Vol.9 (1), p.9-9, Article 9

2023

Volltextzugriff (PDF)

Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020-02, Vol.26 (2), p.289-291

2020

Volltextzugriff (PDF)

Factor X M402T: a homozygous missense mutation identified as the cause of cross-reacting material-reduced deficiency

International journal of hematology, 2014-10, Vol.100 (4), p.345-352

2014

Volltextzugriff (PDF)

The Etiology of Hemophilia Hiding Deep Inside the F8 Intronic Sequence

Blood, 2011-11, Vol.118 (21), p.1223-1223

2011

Volltextzugriff (PDF)

Genotypic and phenotypic features of Japanese patients with mild to moderate hemophilia A

International journal of hematology, 2013-06, Vol.97 (6), p.758-764

2013

Volltextzugriff (PDF)

Acquired hemophilia A

Rinshō ketsueki, 2018, Vol.59 (6), p.756

Amano, Kagehiro

2018

Volltextzugriff (PDF)

Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions

AIDS (London), 2020-11, Vol.34 (14), p.2155-2157

2020

Volltextzugriff (PDF)

ORIHIME II Study: Background, Treatment Status, and Outcomes of Patients with Acquired Hemophilia A with Low Activities of Daily Living Scores or Undergoing Rehabilitation - a Japanese Health Claims Database Analysis

Blood, 2022-11, Vol.140 (Supplement 1), p.5627-5628

2022

Volltextzugriff (PDF)

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

Journal of thrombosis and haemostasis, 2023-03, Vol.21 (3), p.534-545

2023

Volltextzugriff (PDF)

Genetic analysis of carrier status in female members of Japanese hemophilia families

Journal of thrombosis and haemostasis, 2021-06, Vol.19 (6), p.1493-1505

2021

Volltextzugriff (PDF)

Safety and blood loss in spinal surgery for haemophiliacs: Case series of Japanese haemophiliacs

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-01, Vol.27 (1), p.e143-e146

2021

Volltextzugriff (PDF)

Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-01, Vol.27 (1), p.81-89

2021

Volltextzugriff (PDF)

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

The New England journal of medicine, 2023-01, Vol.388 (4), p.310-318

2023

Volltextzugriff (PDF)

Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V

British journal of haematology, 2018-10, Vol.183 (2), p.257-266

2018

Volltextzugriff (PDF)

An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Blood, 2020-11, Vol.136 (Supplement 1), p.26-27

2020

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(87)

Sprache

Englisch
(71)
Japanisch
(31)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(42)
Science & Technology
(42)
Humans
(39)
Hematology
(34)
Male
(20)
Hemophilia
(18)
Hiv
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Middle Aged
(11)
Coagulation Factors
(10)
Adult
(9)
Hematologic And Hematopoietic Diseases
(9)
Hemophilia A - Drug Therapy
(9)
Oncology
(9)
Original Article
(9)
Platelet Diseases And Coagulopathies
(9)
Cardiovascular System & Cardiology
(8)
Factor Viii
(8)
Female
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Coagulation assay discrepancies in Japanese patients with non-severe hemophilia A

Prolonged α-thrombin-related activation and delayed active protein C-associated degradation confer mild phenotype in a patient with severe hemophilia A with F8 p.H118R

In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab

ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database

Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report

Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV

Effects of low and high factor X concentrations on thrombin generation in vitro

Serious hazards of transfusion: evaluating the dangers of a wrong patient autologous salvaged blood in cardiac surgery

Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

Adherence to anti-retroviral therapy, decisional conflicts, and health-related quality of life among treatment-naïve individuals living with HIV: a DEARS-J observational study

Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma

Factor X M402T: a homozygous missense mutation identified as the cause of cross-reacting material-reduced deficiency

The Etiology of Hemophilia Hiding Deep Inside the F8 Intronic Sequence

Genotypic and phenotypic features of Japanese patients with mild to moderate hemophilia A

Acquired hemophilia A

Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions

ORIHIME II Study: Background, Treatment Status, and Outcomes of Patients with Acquired Hemophilia A with Low Activities of Daily Living Scores or Undergoing Rehabilitation - a Japanese Health Claims Database Analysis

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

Genetic analysis of carrier status in female members of Japanese hemophilia families

Safety and blood loss in spinal surgery for haemophiliacs: Case series of Japanese haemophiliacs

Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V

An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Suchergebnisse filtern